Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study

Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study

Abstract Immune checkpoint inhibitors (ICIs) are safe and efficacious treatments for advanced primary liver cancer (PLC). The efficacy of different ICIs in the treatment of liver cancer remains unclear. The purpose of this study was to explore whether there is a difference in the efficacy and safety...

Full description

Bibliographic Details
Main Authors: Qi-mei Li, Qing-can Sun, Yan Jian, Jing-zhe He, Hong-bo Zhu, Chang Hong, Lin Zeng, Rui-ning Li, Jia-ren Wang, Yan Li, Li-ya Chen, Xie Weng, Li Liu, Han-zhi Dong, Lu-shan Xiao, Hao Cui
Format: Article
Language:English
Published: Springer 2023-06-01
Series:Discover Oncology
Subjects:
Primary liver cancer
Immune checkpoint inhibitors
Anti-angiogenesis drug
Combination therapy
Online Access:https://doi.org/10.1007/s12672-023-00708-0

Internet

https://doi.org/10.1007/s12672-023-00708-0

Similar Items